Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia

IF 6.9 2区 医学 Q1 HEMATOLOGY Blood Reviews Pub Date : 2024-04-25 DOI:10.1016/j.blre.2024.101208
Madelyn Burkart , Shira Dinner
{"title":"Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia","authors":"Madelyn Burkart ,&nbsp;Shira Dinner","doi":"10.1016/j.blre.2024.101208","DOIUrl":null,"url":null,"abstract":"<div><p>There have been major paradigm shifts in the treatment of Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) in the last decade with the introduction of new immunotherapies and targeted agents, adoption of pediatric-type chemotherapy protocols in younger adults as well as chemotherapy light approaches in older adults and the incorporation of measurable residual disease (MRD) testing to inform clinical decision making. With this, treatment outcomes in adult Ph- ALL have improved across all age groups. However, a subset of patients will still develop relapsed disease, which can be challenging to treat and associated with poor outcomes. Here we review the treatment of Ph- ALL in both younger and older adults, including the latest advancements and future directions.</p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"66 ","pages":"Article 101208"},"PeriodicalIF":6.9000,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X24000419","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

There have been major paradigm shifts in the treatment of Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL) in the last decade with the introduction of new immunotherapies and targeted agents, adoption of pediatric-type chemotherapy protocols in younger adults as well as chemotherapy light approaches in older adults and the incorporation of measurable residual disease (MRD) testing to inform clinical decision making. With this, treatment outcomes in adult Ph- ALL have improved across all age groups. However, a subset of patients will still develop relapsed disease, which can be challenging to treat and associated with poor outcomes. Here we review the treatment of Ph- ALL in both younger and older adults, including the latest advancements and future directions.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
费城染色体阴性急性淋巴细胞白血病的治疗进展
在过去十年中,随着新型免疫疗法和靶向药物的引入、在年轻成人中采用儿科型化疗方案以及在老年成人中采用轻化疗方法,并将可测量残留疾病(MRD)检测纳入临床决策,费城染色体阴性(Ph-)急性淋巴细胞白血病(ALL)的治疗模式发生了重大转变。因此,所有年龄组的成人非小细胞肺癌治疗效果都有所改善。然而,仍有一部分患者会出现复发,这不仅治疗难度大,而且疗效不佳。在此,我们回顾了年轻和年长成人 ALL Ph 细胞的治疗,包括最新进展和未来方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Blood Reviews
Blood Reviews 医学-血液学
CiteScore
13.80
自引率
1.40%
发文量
78
期刊介绍: Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.
期刊最新文献
Editorial Board Breaking down frailty: Assessing vulnerability in acute myeloid leukemia Longitudinal clinical manifestations of Fanconi anemia: A systematized review Absolute and functional iron deficiency: Biomarkers, impact on immune system, and therapy Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1